Overview

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

Patients with relapsed or refractory Hodgkin Lymphoma who are CD30+ will receive a standard of care reduced intensity regimen and an allogeneic stem cell transplant (from another person, related or unrelated). Following recovery, patients will receive a medication called Brentuximab Vendotin which is targeted against CD30+ cells. The study hypothesis is that this treatment will be safe and well tolerated in children and young adults.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

New York Medical College

Collaborator:

St. Baldrick's Foundation

Treatments:

Antibodies, Monoclonal
Brentuximab Vedotin